Professional Documents
Culture Documents
August 2015
Karan Khanna
karankhanna@ambitcapital.com
Tel: +91 22 3043 3251
Strategy
CONTENTS
Debunking the MNC premium 3
Section 1: Rise of the MNC premium.4
Section 2: Ranking the MNC universe 11
Section 3: Is the MNC premium sustainable?.............................................. 13
Appendix 1: Case studies from our Listed MNCs - 18
The good, the bad and the ugly report
Page 2
Strategy
THEMATIC
Final verdict
Kansai Nerolac
GREEN
CRISIL
GREEN
GREEN
GlaxoSmith Pharma
GREEN
GlaxoSmith C H L
GREEN
Gujarat Pipavav
GREEN
Nestle India
AMBER
Castrol India
AMBER
AMBER
WABCO India
AMBER
Hind Unilever
AMBER
Bosch
AMBER
ACC
AMBER
Colgate-Palmolive India
AMBER
Cummins India
AMBER
Gillette India
AMBER
Pfizer India
AMBER
Whirlpool of India
AMBER
Siemens
RED
RED
Maruti Suzuki*
RED
Ambuja Cement
RED
P&G Hygiene
RED
3M India
RED
ABB India
RED
Analyst Details
2.50
saurabhmukherjea@ambitcapital.com
2.00
1.50
1.00
Jan-10
Jan-11
Jan-12
Jan-13
Jan-14
Jan-15
Karan Khanna
+91 22 3043 3251
karankhanna@ambitcapital.com
Consultant: Anupam Gupta
anupam.gupta@aavanresearch.com
Ambit Capital and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, investors should be aware that Ambit Capital
may have a conflict of interest that could affect the objectivity of this report. Investors should not consider this report as the only factor in making their investment decision.
Strategy
Incorporated
In
1933
Promoter
Holding (%)
67
Market Cap
(Rsbn)
1,964
1981
56
1,345
Bosch Ltd
1951
71
829
1959
63
625
Company
Siemens Ltd
1957
75
543
1981
50
357
1989
75
356
1962
51
320
1924
75
316
1949
75
292
1937
51
276
1958
72
265
ACC Ltd
1936
50
264
1979
71
242
1964
71
210
1984
75
178
1991
75
173
CRISIL Ltd
1987
67
143
1920
69
138
1957
75
137
2004
75
126
3M India Ltd
1987
75
118
Pfizer Ltd/India
1950
64
111
1992
43
104
1960
75
96
Source: Bloomberg, Ambit Capital research; Note: Market-cap as on August 06, 2015
Page 4
Strategy
Investing in MNCs has paid off
Note that the price performance of MNC stocks from the BSE500 universe has been
impressive over multiple time-frames, as shown in the exhibit below.
Exhibit 2: MNCs in general have beaten benchmarks by a large margin
CAGR
1yr
3yr
5yr
10yr
BSE500 Index
16%
23%
12%
16%
MNC universe
49%
30%
22%
21%
had
an
Source: Bloomberg, Ambit Capital research. Note: Prices have been taken as of 21st July 2015. Hence, 1yr
performance compares price performances of BSE500 Index and Top-25 MNC stocks for the period 21st July
2014 to 21st July 2015 and so on for 3yr (2012-2015), 5yr (2010-2015) and 10yr (2005-2015) periods.
Amongst the key reasons behind these firms superior share price performance has
been the way MNCs manage cash, as highlighted in our July 31, 2013 thematic
report, The cash flow conundrum for India Inc, and in the way they bring world-class
technology and professional management methods to India. As a result, across a set
of fundamental metrics like accounting quality (as per Ambits accounting quality
framework), RoCEs and RoEs, MNCs perform better than an average BSE500 firm.
led by superior financials
Median
RoCE
Median
RoE
Median Fixed
Asset turnover
BSE500 Index
192
15%
13%
1.9
MNC universe
213
21%
15%
3.5
Fundamentals
Source: Bloomberg, Company, Ambit Capital research; Note: Accounting score is median accounting score for
the MNC universe and the BSE500 index constituents using our proprietary forensic accounting framework
(click here for more details).
3.00
2.50
2.00
1.50
Jan-15
Apr-15
Oct-14
Jul-14
Apr-14
Jan-14
Oct-13
Jul-13
Apr-13
Jan-13
Oct-12
Jul-12
Apr-12
Jan-12
Jul-11
Oct-11
Apr-11
Jan-11
Oct-10
Jul-10
Jan-10
Apr-10
1.00
Page 5
Strategy
Exhibit 5: MNC market-cap evolution over FY10-15
70%
63%
60%
50%
40%
27%
30%
20%
10%
0%
We illustrate this by using the example of Colgate Palmolive. Over the past five years
(FY10-FY15), Colgates P/E rose to 49x in FY15 from 21x in FY10. Note that 21% of
this increase in P/E was attributable to earnings growth, whilst 75% was attributable
to the re-rating of the P/E multiple for the stock.
Identifying those MNC stocks where valuations are at a disconnect
Delving further into the MNC premium, we analysed stock valuations based on
traditional measures such as P/E compared with earnings growth and P/B compared
with return on equity. Our analysis reveals that MNC stocks like Blue Dart and
Gillette appear to be trading at trailing P/B valuations that are disconnected with
their average ROEs. For example: Blue Darts trailing P/B is at an astronomical 53.6x
versus an average FY09-15 ROE of just 20.3%.
Exhibit 6: Blue Dart and Gillette stand out as outliers on Trailing P/B v/s average
RoEs
R = 41%
60.0
Trailing P/B
50.0
Blue Dart
Castrol
40.0
HUL
Gillette
30.0
P&G
20.0
10.0
-
(20.0)
20.0
40.0
60.0
80.0
FY09-15 average RoE
100.0
120.0
140.0
On a trailing P/E vs FY09-15 EPS CAGR, we highlight ABB India, Alstom T&D,
Siemens and Gillette where trailing P/E valuations are disconnected with earnings
growth. For example, Siemens trades at a trailing P/E of 157.2x even as its FY09-15
earnings fell at an 11% CAGR.
Page 6
Strategy
Exhibit 7: whilst Gillette, ABB India, Alstom T&D and Siemens are outliers on a P/Eearnings growth comparison
Trailing P/E
350
300
Gillette
200
Siemens
ABB
150
Blue Dart
100
Alstom
Pfizer
-20%
R = 36%
250
WABCO
50
GSK Consumer
-10%
0%
10%
20%
30%
Having established that the MNC premium goes beyond earnings-based valuations,
we now delve into subjective reasons for the existence of this premium.
300
R = 23%
250
200
150
100
50
10%
(50)
20%
30%
40%
50%
60%
Page 7
Strategy
50%
40%
30%
20%
10%
0%
-10%
0%
10%
20%
30%
40%
50%
60%
Exhibit 10: Inflows into equity mutual funds have accelerated even in the wake of
intensifying downgrades of Sensex earnings estimates
150
1,800
1,780
1,760
1,740
1,720
1,700
1,680
1,660
1,640
1,620
1,600
120
90
60
30
Jun-15
May-15
Apr-15
Mar-15
Feb-15
Jan-15
Dec-14
Nov-14
Oct-14
Sep-14
Aug-14
Jul-14
Jun-14
May-14
Whilst
consensus
has
been
downgrading its Sensex earnings
estimates, retail inflows into equity
mutual funds have accelerated
Source: Bloomberg, AMFI website, Ambit Capital research. Note: * Assumes 60% of balanced allocation as
equity; these numbers also include allocation to equity arbitrage schemes. This exhibit has been reproduced
without any changes from our July 21, 2015 note: Are investors overpaying for the shelter of earning visibility?
Page 8
Strategy
Exhibit 11: As a result, money flow into the safety trade has continued
1
9000
0.9
8000
0.8
7000
0.7
Bear
6000
0.6
5000
0.5
4000
0.4
Bull
3000
0.3
0.2
2000
0.1
1000
0
Nifty
Mar-03
Jun-03
Sep-03
Dec-03
Mar-04
Jun-04
Sep-04
Dec-04
Mar-05
Jun-05
Sep-05
Dec-05
Mar-06
Jun-06
Sep-06
Dec-06
Mar-07
Jun-07
Sep-07
Dec-07
Mar-08
Jun-08
Sep-08
Dec-08
Mar-09
Jun-09
Sep-09
Dec-09
Mar-10
Jun-10
Sep-10
Dec-10
Mar-11
Jun-11
Sep-11
Dec-11
Mar-12
Jun-12
Sep-12
Dec-12
Mar-13
Jun-13
Sep-13
Dec-13
Mar-14
Jun-14
Sep-14
Dec-14
Mar-15
Jun-15
Source: Ambit Capital research. Note: Grey/red colour bars represent the proportion of bullish/defensive factors working during the quarter. For example, in the
end of the Jun15 quarter, nearly 80% of the factors working were defensive. This exhibit has been reproduced without any changes from our June 03, 2015 note:
Style-based long and short ideas.
Company Name
NEST IN
FY15-17E EPS
CAGR
FY17E P/E
12%
41.6
HUVR IN
18%
37.7
DABUR IN
17%
35.1
BRIT IN
18%
46.8
CLGT IN
14%
36.9
MRCO IN
Marico Ltd
25%
31.1
SKB IN
14%
34.8
Page 9
Strategy
Exhibit 13: Performance of earnings stability quintiles during the bull phase
Q1
CAGR
64%
Q3
63%
Q2
58%
Q4
55%
Q5
49%
Dec-07
May-07
May-06
May-05
May-04
May-03
1,000
900
800
700
600
500
400
300
200
100
0
Source: Bloomberg, Ambit Capital research Note: The above exhibit plots the growth of `100 invested in each of
the five quintiles on earnings stability, from May-03 to Dec-07 (i.e. over the previous bull phase). Q5 (Q1) is the
quintile with the most (least) stable earnings.
Similarly, in the one-year period between May 2013 and May 2014 when the market
rally was characterised by hopes of an economic recovery, low-stability (low-visibility)
stocks yet again outperformed whilst their high-stability (high-visibility) counterparts
underperformed (with Q1 delivering returns of 32% over the year vs 23% delivered by
Q5).
To reiterate, MNC stocks have benefited from this safety trade and, as Indias
economic growth reverts to a normal macro environment, this trade is likely to
unwind.
the
Exhibit 14: Indian operations still not meaningful enough for global parent
Indian listed company profits as a
percentage of their global MNC
parents profits
India-listed MNC
market-cap to global listed MNC
market-cap
On an average basis
7.8%
15.0%
On a median basis
1.9%
7.9%
Source: Bloomberg, Ambit Capital research. Note: Indian listed company profits are for FY15; Global MNC
parent profits are for 2014.
Thus, we believe that delisting is, at best, a flavour-of-the-month theme that comes
and goes with rumours on delisting-related regulation. We do not ascribe any
meaningful permanence to this aspect in the valuation of MNC stocks in general.
In the next section, we rank the top-25 MNCs on Ambits proprietary framework to
understand the justification of their valuation premium.
Page 10
Strategy
Page 11
Strategy
CEO incentivisation
We rank the various MNCs based on incentives received by the CEO. An incentive
structure that aligns local management deliverables with the local shareholders is
superior to one based on share of profits of the parent or share plans linked to
the global parent. If remuneration is linked to earnings of the global parent, the
CEO would be more interested in boosting profits of the global parent than the
Indian subsidiary. Thus, MNCs where the local senior management get stock
options that are linked to the global parent but not the local MNC get a RED flag.
In case of MNCs where the local senior management get stock options in both
the global parent as well as the local MNC, we give an AMBER flag. Finally, we
assign a GREEN flag if the local senior management gets stock options in the
local MNC but not the global parent, or the local senior management does not
get any ESOPs.
Methodology: We allot RED, AMBER and GREEN flags to the response on each of
the seven issues. Flags are in order of importance; a RED flag signals a noticeable
concern, an AMBER flag signals a mild concern, whilst a GREEN flag signals no
major concern. RED flags get a score of zero, AMBER flags get a score of one and
GREEN flags get the highest score of two. Thus, for the seven parameters in our
framework, scores are between 0 and 14.
Page 12
Strategy
Tying it all together
After considering the seven parameters discussed in the previous section, the
consolidated results have been shown in Exhibit 15 below.
Exhibit 15: Top 25 MNCs overall results
Company name
Kansai Nerolac
Green
Green
Amber
Green
Green
Green
Green
Green
CRISIL
Green
Green
Green
Green
Green
Red
Green
Green
Green
Green
Red
Green
Green
Green
Green
Green
GlaxoSmith Pharma
Green
Green
Green
Green
Green
Green
Red
Green
GlaxoSmith C H L
Amber
Green
Green
Green
Green
Green
Red
Green
Gujarat Pipavav
Green
Green (2)
Red
Green
Amber
Green
Green
Green
Nestle India
Red
Green
Green
Green
Green
Green
Red
Amber
Castrol India
Amber
Amber
Green
Green
Green
Green
Red
Amber
Green
Green
Red
Green
Red
Green
Green
Amber
WABCO India
Green
Red
Red
Green
Green
Green
Green
Amber
Hindustan Unilever
Amber
Red
Green
Green
Green
Red
Green
Amber
Bosch
Red
Amber
Amber
Green
Amber
Green
Green
Amber
ACC
Amber
Red
Green
Green
Green
Green
Red
Amber
Red
Amber
Green
Green
Green
Green
Red
Amber
Colgate-Palm
Cummins India
Amber
Amber
Green
Green
Amber
Green
Red
Amber
Gillette India
Amber
Red (2)
Green
Green
Green
Green
Red
Amber
Pfizer India
Green
Amber
Amber
Amber
Green
Green
Red
Amber
Whirlpool of India
Amber
Green
Red
Green
Green
Green
Red
Amber
Siemens
Green
Green
Amber
Red
Green
Red
Amber
Red
Amber
Red
Amber
Green
Green
Green
Red
Red
Red
Amber
Red
Amber
Amber
Green
Green
Red
Amber
Red
Amber
Red
Green
Green
Amber
Red
Red
Green
Amber
Green
Red
Green
Red
Red
3M India
Red
Red
Red
Green
Green
Green
Red
Red
ABB India
Red
Red
Amber
Amber
Green
Red
Green
Red
Source: Company, Ambit Capital research. Note: * Ambit has a bottom-up BUY on Maruti Suzuki. (1) Royalty & related payments includes the following nature of
payments: Royalty, payments towards general license fees, Training & technical consultancy fees, License agreements, Trademark fees, Fees for availing IT,
engineering, management & other services, Corporate management fees and fees for technical know-how. (2) CAGR in royalty & related payments vs CAGR in net
sales has been calculated over FY10-14 as the same could not be calculated over FY09-14. (3) Dividend payments include both interim as well as final dividend.
We rank the overall score and the key reasons driving them in the exhibit below.
Page 13
Strategy
Exhibit 16: Ranking and rationale behind MNC scores
Company name
Score
Flag level
Kansai Nerolac
13
GREEN
CRISIL
12
Key reasons
FY16 P/E
FY16 P/B
37.1
7.3
GREEN
Scores well across all the parameters; but misses on share price
performance pre-open offer
48.2
15.1
12
GREEN
25.5
8.3
GlaxoSmith Pharma
12
GREEN
52.0
16.3
GlaxoSmith C H L
11
GREEN
37.6
10.6
Gujarat Pipavav
11
GREEN
24.4
4.7
Nestle India
10
AMBER
55.4
20.9
Castrol India
10
AMBER
37.1
42.6
10
AMBER
80.6
23.1
WABCO India
10
AMBER
60.8
12.0
Hind Unilever
AMBER
43.0
42.8
Bosch
AMBER
56.9
9.7
ACC
AMBER
27.9
3.1
Colgate-Palm
AMBER
43.6
30.4
Cummins India
AMBER
36.6
10.1
Gillette India
AMBER
343.2#
27.4#
Pfizer India
AMBER
37.8
6.3
Whirlpool of India
AMBER
37.4
8.5
Siemens
RED
72.0
9.7
RED
61.9
9.4
Maruti Suzuki*
RED
26.0
4.8
Ambuja Cem
RED
25.1
2.9
P&G Hygiene
RED
65.4
17.8
3M India
RED
107.5#
14.4#
ABB India
RED
94.5
9.7
Source: Company, Bloomberg, Ambit Capital research. Note: * Ambit has a bottom-up BUY on Maruti Suzuki. # indicates this is on a trailing basis since FY16
estimates are no available.
Page 14
Strategy
Section
3:
sustainable?
Is
the
MNC
premium
But it remains the case that you know what is wrong with a lot more
confidence than you know what is right.
- Nassim Nicholas Taleb in The Black Swan: The Impact of the Highly Improbable
(2007)
Indias upcoming phase of reform-led growth will not materially expand the
MNC premium. MNCs have shown ways to capture this growth outside the
listed Indian arm. Moreover, the experience of other countries tells us that as
countries become richer, competitive intensity rises and RoEs gradually
decline. Both these factors will restrict if not reduce the MNC premium in
the future.
Exhibit 17: How structural reforms drive up growth rates in the long term
Country/Period
Britain under Margaret Thatcher (1979-90)
India (1991-02)
Indonesia (1997-06)
Page 15
Strategy
In the exhibit below, we list those MNCs that have unlisted subsidiaries in India and
we compare their FY14 revenues.
Exhibit 18: Comparison of listed and unlisted arms of select MNCs
270%
247%
177%
Cummins India
73%
Bosch
55%
Source: Company, Bloomberg, Ambit Capital research. Note: *APM Terminals (i.e. the holding company of
Gujarat Pipavav) also operates the Gateway terminal at Nhava Sheva and other logistics business and does
container transportation which does not compete with Gujarat Pipavav Port.
As seen above, not all of the top-25 MNCs have unlisted subsidiaries. However, in
high-profile cases, investors have raised concerns when MNCs resort to route
business through unlisted subsidiaries.
Case study 1: Maruti Suzuki
What was proposed?
On January 28, 2014, the Board of Maruti Suzuki approved the implementation of
the expansion of its Gujarat plant through a 100% Suzuki subsidiary. As per the terms
of the contract, the plant would be operated by Suzuki Motors Gujarat Pvt Ltd
(SMGPL), a wholly-owned subsidiary of Suzuki Motor Corporation (SMC); and Maruti
would only make payments towards the cost of production plus adequate cash
necessary to meet incremental capex requirements. The land for the project would be
leased by Maruti to the wholly-owned subsidiary, which would then make lease
payments, determined at an arms length basis, for the use of land.
The move to set up Suzukis 100% subsidiary raised several concerns
As highlighted by our Auto analyst, Ashvin Shetty, in his January 29, 2014 note
(click here for the detailed note) and followed up with 13th February 2014 note A
new passage to India? (click here for the detailed note), the proposal to set up a
separate subsidiary for the Gujarat plant raises several concerns such as:
Rationale for this unusual move of setting up a separate Suzuki subsidiary is not
clear.
Being a private limited company, the cost of production would not be known.
Whilst Maruti prefers sourcing raw materials locally, it is unclear whether the
wholly owned subsidiary would rely on imports or prefer localisation.
As a result of the arrangement, Maruti would only be earning the
selling/distribution margins on vehicles manufactured at the Gujarat plant.
Whilst capex for the initial phase would be incurred by SMC, capex for future
phases would be indirectly funded by Maruti (given that Maruti would be making
payments for incremental capex requirements).
Some positive steps taken by the company to address the above concerns
Marutis stock price declined over 8% on the day of the announcement of the project
(January 28, 2014) and in subsequent months, institutional investors opposed the
proposal (Read news article: http://goo.gl/w9x6A1).
The company took some steps to address the above investor concerns. In March
2014, the Board of the company significantly altered the terms of the above
arrangement with Suzuki. The key changes were:
a) Vehicle pricing at cost vs earlier cost plus mark-up: Compared with the
earlier announcement of cost plus mark-up, the revised terms stated that the
pricing of vehicles from WoS to Maruti would only include only the cost of
production including depreciation.
Page 16
Strategy
b) Transfer of assets at book value: Compared with the earlier
announcement, which stated that the assets of WoS (if the agreement is
terminated) would be transferred to MSIL at 'fair value', the new clarification given
by the management indicated that it would be transferred at 'book value'.
c) The board also decided to seek the approval of minority shareholders on the
proposal.
Current Status
Whilst the company sought to allay investor concern with various clarifications, as
discussed above, it remains firm on setting up the plant. In July 2015, Chairman, RC
Bhargava said We were hoping to do it by September but there has been some
delay in Gujaratit got delayed by a couple of months. They are yet to give the
formal approval for the SSA (state support agreement) getting transferred from
Maruti to Suzuki. We are hoping it will happen this month. And the moment that
happens, we will work out a scheduleIt will happen within this calendar year
certainly. (Source: http://goo.gl/Np9iki)
We also note that in apparent recognition of its low dividend payout, the companys
Board in Oct 2014, along with its 2QFY15 results, adopted a guideline to raise
dividend payout to 18-30% of net profits, up from the average dividend pay-out of
11.5% over FY11-14.
Our primary concerns at this point on this likely arrangement are: (i) how would the
fairness of the related party transactions would be ensured would the minority
shareholders of Maruti get an opportunity to vote on transactions between Suzuki
and its 100% owned Indian subsidiary; (ii) Impact on Marutis margin due to any
change in the level of localisation at the Gujarat plant under Suzukis 100%
subsidiary and had the plant been under Maruti?
Case study: P&G Hygiene & Healthcare
The Procter & Gamble Company, USA has three Indian entitiesP&G Home Products,
P&G Hygiene and Healthcare, and Gillette India. Out of the three companies, only
P&G Home Products is an unlisted entity. This entity comprises the detergents, hair
care and skin care businesses. Whilst the new launches made by the company are not
in the public domain, anecdotal data on P&Gs aggression in the market-place
suggests that P&G has been very active in the segments in which it operates.
Whilst P&G Home Products has seen a revenue CAGR of 24% over FY01-13, P&G
Hygiene & Healthcare has seen a revenue CAGR of only 13% over the same period.
This implies that the revenue growth of the unlisted arm has been ~1.9x the revenue
growth of the listed entity. Further, its revenue as a percentage of the listed entity has
increased from 93% in FY01 to 286% in FY13 (see Exhibit 19).
Exhibit 19: P&G Company, USA - Operations outside the listed entity in India
Growth in revenues of unlisted subsidiaries/ companies
outside the listed entity
FY2001
FY2002
89%
-3%
FY2003
82%
0%
FY2004
89%
41%
FY2005
102%
36%
FY2006
143%
FY2007
184%
22%
FY2008
202%
31%
Year
16%
FY2009
165%
-2%
FY2010
233%
65%
FY2011
284%
36%
FY2012
303%
38%
FY2013
286%
23%
Source: Company, Ambit Capital research; Note: For the purpose of calculation of revenues of unlisted group entities as a percentage of listed subsidiaries, only
P&G Hygiene & Healthcare has been considered in the listed entity
Page 17
Strategy
Reason 2: Rising competitive intensity will hit premium valuations
In our May 14, 2014 thematic report, Can India turn back the clock?, we argued that
better governance in India should be positive for the country, as corruption and
inflation eases and Indias competitiveness improves. However, this process will
produce not just winners but also losers i.e. companies that have benefited from the
muted competitive environment in India over the past decade. As a result, the
valuation premium that the market has been willing to pay for better-run companies
including MNCs will ERODE. On the other hand, companies which were held back
due to the high cost of capital and due to regulatory distortions stand to perform well.
Cross-country data shows that as countries become richer, RoEs decline. We expect
this impact to play out in India as well. An uptick in economic growth will raise
competitive intensity and drive operating/PAT margins lower. This, in turn, will drive
high RoEs one of the key drivers for MNC premium lower. We tracked the rise in
per capita income of Brazil, India, Indonesia, Thailand and Turkey and compared this
rise with the RoE of each countrys benchmark equity index. The results in the
exhibits below - show a trend of declining RoEs, as countries become richer.
India
30.0
RoE (%)
Turkey
20.0
Indonesia
10.0
Thailand
CY-14
CY-13
CY-12
CY-11
CY-10
CY-09
CY-08
CY-07
CY-06
CY-05
CY-04
CY-03
CY-02
-10.0
CY-01
0.0
Brazil
14,000
12,000
10,000
Turkey
8,000
6,000
Thailand
4,000
Indonesia
2,000
CY-14
CY-13
CY-12
CY-11
CY-10
CY-09
CY-08
CY-07
CY-06
CY-05
CY-04
CY-03
CY-02
CY-01
Exhibit 21: Per capita income (USD) trends since 2001 for select countries
India
Reason 3: MNCs will use creative methods to remove money from the listed
entity
Finally, we repeat our core thesis from our March 07, 2014 thematic report,
Listed MNCs - The good, the bad & the ugly. MNCs can use a variety of creative
methods to short-change minority shareholders to remove money from the listed
entity. We summarise these methods below:
(1) High royalty payments
Royalty payment is perhaps the most common (and also the easiest) way in which
foreign promoters can pull out cash from their Indian subsidiaries. Higher royalty
payment (after the Indian Government removed the cap on royalty payments in
2010) has two adverse impacts. Firstly, as more and more royalty payments are made
to the foreign parent, minority shareholders have to bear the brunt in the form of
Page 18
Strategy
lower profits and lower dividend payouts. Secondly, royalty hikes have an adverse
impact for the Indian tax authorities as well. This is because whilst royalty payments
are taxed at 10%, corporate income in India is taxed at 30%.
(2) Merging unlisted entities at high valuations
In order to milk cash from their listed subsidiaries, we often find MNC parents
resorting to merging their unlisted subsidiary with the listed Indian subsidiary at
stratospheric valuations, that too without visible synergies.
(3) Transfer of profitable divisions at low valuations
In direct contrast to the point on mergers above, it is also possible that a profitable
division of the listed entity could be spun-off/transferred to the global parent at
relatively low valuations.
(4) Cash repatriation from subsidiary to parent
Ideally, cash held by the subsidiary belongs as much to the minority shareholders as it
does to the controlling shareholder. However, in recent times, we have seen how the
parent can abuse its position as the dominant shareholder to pull out cash from the
subsidiary, as the minority shareholders are not in a position to say much about it.
(5) Competing unlisted subsidiaries
There have been instances in the past where a foreign parent decides to set up other
subsidiaries in addition to the local listed subsidiary. Whilst the rationale of setting up
another subsidiary is often not clear, on the face of it this implies opportunity loss for
the local listed subsidiarys business.
(6) Business transactions with the Indian subsidiary at unfavorable terms
Another manner in which MNCs have historically short-changed minorities is by
conducting business with its local arm on favourable terms for the parent.
(7) Incentivisation of local management
An incentive structure that seeks to reward the local management by aligning their
deliverables with the shareholders of the parent and not with that of the Indian
entitys shareholders leaves room for suspicion on corporate governance.
For a summary of the case studies on how MNCs have used the above methods,
please refer Appendix 1.
Flagging off MNCs at risk
For the seven companies marked RED on our framework in Section 2, we highlight
ABB India, Siemens and Alstom T&D India as outliers on P/E vs EPS CAGR,
highlighted in Exhibit 7 above and reproduced below. With valuations clearly
disconnected with the underlying earnings, we believe these stocks are particularly
exposed, given their track record of minority-unfriendliness.
Trailing P/E
Exhibit 22: ABB India, Siemens and Alstom T&D are outliers on P/E vs earnings growth
Gillette
Siemens
ABB
-20%
Alstom
Pfizer
R = 36%
350
300
250
200
150
100
50
-
-10%
Blue Dart
WABCO
GSK Consumer
0%
10%
20%
30%
Page 19
Strategy
Even though the companys volume growth had been declining over the past
several quarters, it had increased the royalty payments. Whilst peers such as
Godrej Consumers, ITC, Marico and Nestle had recorded an average three-year
and five-year CAGR in sales of 26% and 24% respectively, HULs sales growth
was much lower at 15% and 14% respectively. Given the declining market share,
the royalty hikes did not seem justified.
Growth in royalty and related payments had exceeded sales growth in three of
the last four years (see Exhibit 23). Also, whilst sales and PAT had recorded a
CAGR of 12% and 17% respectively over FY09-13, royalty payments made to
Unilever (and fellow subsidiaries) had recorded a CAGR of 31% over the same
period (see Exhibit 24). Thus, growth in royalty payments was ~2.5x and ~1.8x
the growth in net sales and PAT respectively. Such a vast difference between the
two raises concerns regarding whether the royalty/technical collaboration from
Unilever was indeed meant to help HUL or was it merely a means of siphoning
off cash by the controlling shareholder at the expense of minority shareholders.
Exhibit 23: HUL - Royalty growth has exceeded sales growth in three of the last four
years
60%
50%
40%
30%
20%
10%
0%
FY10
FY11
YoY growth in royalty
FY12
FY13
Page 20
Strategy
Exhibit 24: HUL - Royalty CAGR vs net sales and PAT CAGR
(in ` mn)
FY09*
FY10
FY11
FY12
FY13
FY09-13 CAGR
1,304
1,869
2,868
3,160
3,882
31%
PAT
19,972
22,020
23,060
26,914
37,967
17%
161,915
175,238
197,355
221,164
258,102
12%
Royalty as a % of PAT
6.5%
8.5%
12.4%
11.7%
10.2%
0.8%
1.1%
1.5%
1.4%
1.5%
Net Sales
Source: Company, Ambit Capital research; Note: standalone figures. *Data for FY09 has been annualised
As per the provisions of the Companies Act 2013, related party transactions
would require prior approval of the company by a special resolution. Further, a
member who is a related party is not entitled to vote on such special resolutions.
Thus, it could also be possible that the royalty hikes were announced before these
stringent provisions under the new Act could come into force. The Companies Bill
was passed by the Lok Sabha in December 2012.
Four months later, Unilever had announced an open offer to raise its stake in
HUL up to 75%. A royalty hike announced few months before the open offer does
not seem to be a mere coincidence (see Exhibit 25).
As a result, the royalty hike announcement, which was not in the interests of minority
shareholders, was not welcomed by investors.
Exhibit 25: HULs stock was underperforming
announcement of the open offer
120.0
the
FMCG
Index
before
the
110.0
100.0
90.0
80.0
Jan-13
Feb-13
HUL
Mar-13
Apr-13
Source: Bloomberg, Ambit Capital research; Note: Both HULs share price and BSE FMCG Index have been
rebased to 100 at the start of January 2013
Page 21
Strategy
Out of the three divisions of HP-ISO: HP Labs, software technology centre and the
software engineering services division, only one of the three divisions, i.e., the
software engineering division, seemed to have cost synergies with Digital
GlobalSoft. (Source: http://goo.gl/RGTjwA)
850.0
750.0
HP announces
open offer; shares
surge 12%
650.0
550.0
450.0
350.0
Apr-02
Jul-02
Oct-02
Jan-03
Apr-03
Jul-03
Oct-03
Jan-04
Page 22
Strategy
However, even before the demerger proposal could sail through, top executives from
HP had quit the company (Source: http://goo.gl/bbTqfl).
Further, in November 2003, HP announced an open offer to buy out the minority
shareholders in Digital GlobalSoft at `750/share in order to delist its equity shares
from all the stock exchanges. At this price, HP would have had to shell out ~`12.5bn
to buy out the minority shareholders. As a result, Digital GlobalSofts shares surged
12% the next day.
The delisting proposal, however, required the approval of the shareholders by a
special resolution, to sail through. Whilst the minority shareholders raised concerns
on the delisting price, the proposal could eventually receive the shareholders nod in
the EGM held in January 2004, as 20.3mn votes were cast in favour of it whilst less
than 0.1mn votes were cast against it. (Note: As the company filings are not available
on the BSE as well as NSE given that it is now delisted, this information is based on
press articles (Source: http://goo.gl/sP0DOY)). As a result, the shares were delisted in
April 2004. The price for acquisition was, however, raised to `850/share under the
reverse book-building process.
A merger announcement few months before the delisting announcement, which
resulted in a depressed share price, shows poor corporate governance on the part of
HP. The floor price under SEBI norms was `566/share. Had Digital GlobalSofts share
price not been hammered post the BoDs approval of the merger, the floor price (and
consequently the final exit price) would have been much higher.
PBT margins
Sep-07
1,600
10,230
15.6%
Sep-08
730
9,940
7.3%
Page 23
Strategy
This was not the first time where a division had seen a decline in profitability
immediately before the transfer to Siemens AG. There had been multiple instances in
the past wherein the Board had approved the divestment of a particular segment in
favour of Siemens AG as part of the global alignment process. For example, in
February 2007, the Board had approved the proposal for the sale and transfer of the
Siemens Communications Enterprise Networks (COM EN) Division to Siemens
Enterprise Communications Pvt Ltd (SECPL), a 100% subsidiary of Siemens AG. The
COM EN division had been transferred on a slump sale basis, as a going concern for
a total consideration of ~`609mn w.e.f. August 01, 2007.
Likewise, in April 2007, the company had sold its entire 100% stake (12.43mn equity
shares of `10 each) in Siemens Public Communication Networks Pvt Ltd (SPCNL) to
Nokia Siemens Networks Pvt Ltd, a Nokia Siemens 50:50 joint venture company.
SPCNL was valued at `1,898mn for the purpose of this transfer.
Whilst both these proposals could get all the required clearances, both these divisions
had seen a significant deterioration in profitability before the transfer (see Exhibits 11
and 12).
Exhibit 28: The COM EN division had seen a significant
decline in profitability
Exhibit 29: as
transfer
did
SPCNL
immediately
before
the
(in ` mn)
FY06
FY07*
(in `mn)
FY06
FY07*
Turnover
Turnover
1,358
1,389
6,190
4,669
PBT
132
106
PBT
368
234
PAT
88
70
PAT
207
113
PBT margins
9.7%
7.6%
PBT margins
6.0%
5.0%
PAT margins
6.5%
5.0%
PAT margins
3.3%
2.4%
Source: Company, Ambit Capital research; Note: * Sold on Apr 27, 2007
Both these issues led to investors laying serious allegations on the company relating
to corporate governance issues and tampering with financial statements (Source:
http://goo.gl/jGNAfn).
As a result, both these announcements were not welcomed favourably by the markets
(see Exhibit 30).
Exhibit 30: Both the SISL and SIPS divestments were not welcomed by the markets
120.0
100.0
80.0
60.0
40.0
Nov-08
Dec-08
Siemens
Jan-09
BSE Capital goods Index
Source: Bloomberg, Ambit Capital research; Note: Both Siemens share price and the BSE Capital Goods Index
have been rebased to 100 at the start of November 2008
Page 24
Strategy
It is difficult to decipher how the transaction in which the cash is taken from
Ambuja and replaced with investment in ACC makes the capital structure of the
standalone Ambuja entity any better.
Holcim gets to take out `35bn cash, at only the promise of some future synergies.
The synergy potential of `9bn is not likely to accrue in the near future (see Exhibit
16).
Exhibit 33: Expected synergies and benefits highlighted by the management to be extracted over the next two years
Source
Through
Our view
`3.6bn-4.2bn
`4.2bn-4.8bn
Total
`7.8bn-9bn
Page 25
Strategy
The eventual outcome
As discussed earlier, under the new norms proposed by SEBI, issuance of new shares
to the promoter or promoter group in deals involving acquisitions, mergers and
demergers would require a simple majority (i.e. 51%) of non-promoter shareholding
for passing such a resolution.
The results of the postal ballot conducted were as under:
~87% of the institutional shareholders had voted, of which ~68% had voted in
favour of the resolution whilst just over 32% had voted against the resolution.
Only ~10% of the remaining public shareholders had voted, of which ~88% had
voted in favour of the resolution whilst less than 12% had voted against the
resolution.
Thus, in spite of widespread criticism of the deal and opposition from minority
shareholders, Ambuja could get 68.5% of public shareholder votes in favour of the
deal. Post that, Ambuja had also received the EGM approval for a reduction in its
share capital. As a result of this scheme, Holcims stake in Ambuja will go up by 10%
whilst the minority shareholders stake will be diluted by over 20%.
Page 26
Strategy
Financial year
FY08*
FY09
70.0
FY10
71.0
FY11
66.0
Source: Annual filings, Ambit Capital research; Note: * 7 months ending Oct-08
1QFY10
1QFY11
YoY growth
Revenues
11,916
12,335
3.5%
Operating profit
2,678
2,215
-17.3%
3,008
2,562
-14.8%
2,683
2,267
-15.5%
Source: Company, Ambit Capital research; Note: Mphasis follows a Nov-Oct financial year; hence 1Q indicates
results for the Nov-Jan quarter
Exhibit 36: even though strong results were reported by tier-1 IT firms
(in `mn)
Revenues
PAT
Oct-Dec' 10
Oct-Dec' 09
growth (YoY)
Oct-Dec' 10
Oct-Dec' 09
growth (YoY)
Infosys
71,060
57,410
24%
17,800
15,820
13%
Wipro
78,293
69,634
12%
13,099
12,035
9%
TCS
96,634
76,485
26%
23,965
18,442
30%
HCL Tech*
16,491
12,137
36%
2,860
2,554
Average
25%
12%
16%
Source: BSE filings, Ambit Capital Research; Note: *standalone results for HCL Tech
Page 27
Strategy
As HPs interests as the largest customer took precedence over the minority
shareholders interests, Mphasis share price declined more than 28% in a single
days trading (see Exhibit 37).
Exhibit 37: Precedence of HPs interests as the largest customer over minority
shareholders interests led to a battering of Mphasis stock price
120.0
100.0
80.0
Post the Q1 results,
shares declined 28% in
a single day's trading
60.0
40.0
Jan-11
Feb-11
Mphasis
Mar-11
BSE Technology Index
Source: Bloomberg, Ambit Capital research; Note: Both Mphasis share price and the BSE Technology Index have
been rebased to 100 at the start of January 2011
ABB
ACC
Ambuja Cem.
Bosch
Castrol India
Colgate-Palm.
Cummins India
Glaxosmit Pharma
GlaxoSmith C H L
No
No
No
No
Yes
Yes
Yes
Yes
Hind. Unilever
Maruti Suzuki
Nestl India
Yes
No
No
No
No
Yes
Oracle Fin.Serv.
Yes
No
P & G Hygiene
Siemens
No
Yes
Yes
Yes
Page 28
Strategy
Our findings suggest that the incentive structure of the local senior management of
ACC, Castrol, Colgate-Palmolive, Cummins, GSK Pharma, GSK Consumer,
Nestl India, P&G Hygiene and Siemens includes ESOPs of the global parent,
suggesting that their interests are also aligned to some extent to that of the global
parent. The senior management of Ambuja Cements and Siemens are entitled to
ESOPs in both the listed subsidiary as well as the global parent.
Further, whilst the senior management of ABB does not have ESOPs in the global
parent, certain employees are entitled to purchase shares of ABB Ltd, Zurich, under
the ABB employee share acquisition plan.
On the other hand, the incentive structure of the senior management of HUL and
Oracle Financial Services appears to be more closely linked to the interests of
shareholders of the local subsidiary.
Page 29
Strategy
(022) 30433174
saurabhmukherjea@ambitcapital.com
Research
Analysts
Industry Sectors
(022) 30433241
Desk-Phone E-mail
nitinbhasin@ambitcapital.com
(022) 30433239
aadeshmehta@ambitcapital.com
Midcaps
(022) 30433085
abhishekr@ambitcapital.com
Cement / Infrastructure
(022) 30433178
achintbhagat@ambitcapital.com
Aditya Bagul
Consumer
(022) 30433264
adityabagul@ambitcapital.com
Aditya Khemka
Healthcare
(022) 30433272
adityakhemka@ambitcapital.com
Automobile
(022) 30433285
ashvinshetty@ambitcapital.com
Bhargav Buddhadev
(022) 30433252
bhargavbuddhadev@ambitcapital.com
Deepesh Agarwal
(022) 30433275
deepeshagarwal@ambitcapital.com
(022) 30433255
gauravmehta@ambitcapital.com
Karan Khanna
Strategy
(022) 30433251
karankhanna@ambitcapital.com
(022) 30433206
pankajagarwal@ambitcapital.com
Healthcare
(022) 30433212
pareshdave@ambitcapital.com
(022) 30433223
paritaashar@ambitcapital.com
Derivatives
(022) 30433218
prashantmittal@ambitcapital.com
Consumer / Retail
(022) 30433201
rakshitranjan@ambitcapital.com
Ravi Singh
(022) 30433181
ravisingh@ambitcapital.com
(022) 30433242
riteshgupta@ambitcapital.com
Consumer
(022) 30433246
riteshvaidya@ambitcapital.com
Economy / Strategy
(022) 30433175
ritikamankar@ambitcapital.com
Ritu Modi
Automobile
(022) 30433292
ritumodi@ambitcapital.com
Sagar Rastogi
Technology
(022) 30433291
sagarrastogi@ambitcapital.com
Sumit Shekhar
Economy / Strategy
(022) 30433229
sumitshekhar@ambitcapital.com
Technology
(022) 30433209
utsavmehta@ambitcapital.com
Vaibhav Saboo
(022) 30433261
vaibhavsaboo@ambitcapital.com
Sales
Name
Regions
UK
Desk-Phone E-mail
Dharmen Shah
India / Asia
(022) 30433289
dharmenshah@ambitcapital.com
Dipti Mehta
India / USA
(022) 30433053
diptimehta@ambitcapital.com
Hitakshi Mehra
India
(022) 30433204
hitakshimehra@ambitcapital.com
Krishnan V
India / Asia
(022) 30433295
krishnanv@ambitcapital.com
USA / Europe
(022) 30433259
nityamshah@ambitcapital.com
UK / USA
(022) 30433169
pareespurohit@ambitcapital.com
Praveena Pattabiraman
India / Asia
(022) 30433268
praveenapattabiraman@ambitcapital.com
Shaleen Silori
India
(022) 30433256
shaleensilori@ambitcapital.com
Singapore
pramodgubbi@ambitpte.com
Shashank Abhisheik
Singapore
shashankabhisheik@ambitpte.com
Singapore
USA / Canada
Ravilochan Pola - CEO
Americas
ravipola@ambitpte.com
Production
Sajid Merchant
Production
(022) 30433247
sajidmerchant@ambitcapital.com
Sharoz G Hussain
Production
(022) 30433183
sharozghussain@ambitcapital.com
Joel Pereira
Editor
(022) 30433284
joelpereira@ambitcapital.com
Nikhil Pillai
Database
(022) 30433265
nikhilpillai@ambitcapital.com
Page 30
Strategy
Explanation of Investment Rating
Investment Rating
BUY
>10%
SELL
<10%
NO STANCE
We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation
UNDER REVIEW
We will revisit our recommendation, valuation and estimates on the stock following recent events
NOT RATED
We do not have any forward looking estimates, valuation or recommendation for the stock
Disclaimer
This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Ambit Capital. AMBIT Capital Research is disseminated and available primarily electronically,
and, in some cases, in printed form.
Additional information on recommended securities is available on request.
Disclaimer
1.
2.
3.
4.
5.
6.
7.
AMBIT Capital Private Limited (AMBIT Capital) and its affiliates are a full service, integrated investment banking, investment advisory and brokerage group. AMBIT Capital is a Stock Broker, Portfolio
Manager and Depository Participant registered with Securities and Exchange Board of India Limited (SEBI) and is regulated by SEBI
AMBIT Capital makes best endeavours to ensure that the research analyst(s) use current, reliable, comprehensive information and obtain such information from sources which the analyst(s) believes
to be reliable. However, such information has not been independently verified by AMBIT Capital and/or the analyst(s) and no representation or warranty, express or implied, is made as to the
accuracy or completeness of any information obtained from third parties. The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this
Research Report which are subject to change and do not represent to be an authority on the subject. AMBIT Capital may or may not subscribe to any and/ or all the views expressed herein.
This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of
this Disclaimer, your sole and exclusive remedy is to stop using this Research Report and AMBIT Capital or its affiliates shall not be responsible and/ or liable for any direct/consequential loss
howsoever directly or indirectly, from any use of this Research Report.
If this Research Report is received by any client of AMBIT Capital or its affiliate, the relationship of AMBIT Capital/its affiliate with such client will continue to be governed by the terms and conditions
in place between AMBIT Capital/ such affiliate and the client.
This Research Report is issued for information only and the 'Buy', 'Sell', or Other Recommendation made in this Research Report such should not be construed as an investment advice to any
recipient to acquire, subscribe, purchase, sell, dispose of, retain any securities and should not be intended or treated as a substitute for necessary review or validation or any professional advice.
Recipients should consider this Research Report as only a single factor in making any investment decisions. This Research Report is not an offer to sell or the solicitation of an offer to purchase or
subscribe for any investment or as an official endorsement of any investment.
This Research Report is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied in
whole or in part, for any purpose. Neither this Research Report nor any copy of it may be taken or transmitted or distributed, directly or indirectly within India or into any other country including
United States (to US Persons), Canada or Japan or to any resident thereof. The distribution of this Research Report in other jurisdictions may be strictly restricted and/ or prohibited by law or contract,
and persons into whose possession this Research Report comes should inform themselves about such restriction and/ or prohibition, and observe any such restrictions and/ or prohibition.
Ambit Capital Private Limited is registered as a Research Entity under the SEBI (Research Analysts) Regulations, 2014.
Conflict of Interests
8.
9.
In the normal course of AMBIT Capitals business circumstances may arise that could result in the interests of AMBIT Capital conflicting with the interests of clients or one clients interests conflicting
with the interest of another client. AMBIT Capital makes best efforts to ensure that conflicts are identified and managed and that clients interests are protected. AMBIT Capital has policies and
procedures in place to control the flow and use of non-public, price sensitive information and employees personal account trading. Where appropriate and reasonably achievable, AMBIT Capital
segregates the activities of staff working in areas where conflicts of interest may arise. However, clients/potential clients of AMBIT Capital should be aware of these possible conflicts of interests and
should make informed decisions in relation to AMBIT Capitals services.
AMBIT Capital and/or its affiliates may from time to time have or solicit investment banking, investment advisory and other business relationships with companies covered in this Research Report and
may receive compensation for the same.
AMBIT Capital is not registered in the Province of Ontario and /or Province of Qubec to trade in securities and/or to provide advice with respect to securities.
AMBIT Capital's head office or principal place of business is located in India.
All or substantially all of AMBIT Capital's assets may be situated outside of Canada.
It may be difficult for enforcing legal rights against AMBIT Capital because of the above.
Name and address of AMBIT Capital's agent for service of process in the Province of Ontario is: Torys LLP, 79 Wellington St. W., 30th Floor, Box 270, TD South Tower, Toronto, Ontario M5K 1N2
Canada.
23. Name and address of AMBIT Capital's agent for service of process in the Province of Montral is Torys Law Firm LLP, 1 Place Ville Marie, Suite 1919 Montral, Qubec H3B 2C3 Canada.
Disclosure
24. Ambit and/or its associates have financial interest in Castrol India, Colgate Palmolive, Cummins India, HUL, Maruti, Wabco India and Alstom T&D.
25. Anupam Gupta and/or his relatives have financial interest in Nestle.
Analyst Certification
Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views
about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this
report.
Ambit Capital Pvt. Ltd.
Ambit House, 3rd Floor. 449, Senapati Bapat Marg,
Lower Parel, Mumbai 400 013, India.
Phone: +91-22-3043 3000 | Fax: +91-22-3043 3100
CIN: U74140MH1997PTC107598
www.ambitcapital.com
Page 31